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Limited studies of the association between BDNF levels and delirium have given inconclusive results.This prospective, longitudinal
study examined the relationship between BDNF levels and the occurrence of and recovery fromdelirium. Participants were assessed
twice weekly using MoCA, DRS-R98, and APACHE II scales. BDNF levels were estimated using an ELISA method. Delirium was
defined with DRS-R98 (score > 16) and recovery from delirium as ≥2 consecutive assessments without delirium prior to discharge.
We identified no difference in BDNF levels between those with and without delirium. Excluding those who never developed
delirium (𝑛 = 140), we examined the association of BDNF levels and other variables with delirium recovery. Of 58 who experienced
delirium, 39 remained delirious while 19 recovered. Using Generalized Estimating Equations models we found that BDNF levels
(Wald 𝜒2 = 7.155; df: 1, 𝑝 = 0.007) and MoCA (Wald 𝜒2 = 4.933; df: 1, 𝑝 = 0.026) were associated with recovery. No significant
association was found for APACHE II, dementia, age, or gender. BDNF levels do not appear to be directly linked to the occurrence
of delirium but recovery was less likely in those with continuously lower levels. No previous study has investigated the role of BDNF
in delirium recovery and these findings warrant replication in other populations.
1. Introduction
Delirium is a neuropsychiatric syndrome characterized by
abrupt disturbance in attention, awareness, consciousness,
and cognition. It is frequently accompanied by a variety
of behavioural disturbances, altered psychomotor activity,
disruption of sleep-wake cycle, and psychosis. These distur-
bances develop over a short period and tend to fluctuate.
[1]. Although delirium has classically been characterized
as a highly reversible and relatively transient phenomenon,
accumulating evidence indicates that inmany cases it persists
and is associated with serious adverse longer-term outcomes
(including cognitive and functional deterioration, high rates
of mortality, and prolonged hospitalisation) especially in
older populations [2, 3]. Delirium often occurs in the context
of infectious illness and thus a number of studies have
investigated cytokine levels in an effort to illuminate the
pathophysiology of delirium, but with inconclusive and
conflicting results [4]. In contrast, previous work [5] found
that low levels of neuroprotective factors (IGF-I and IL-1RA)
were associated with delirium.
Brain-Derived Neurotrophic Factor (BDNF) is a medi-
ator of neuronal development [6] that promotes the survival
of neurons [7] and is important for cell proliferation [8]
and inflammatory processes [9, 10]. It has been reported
that BDNF is associated with the pathogenesis of several
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neuropsychiatric disorders such as schizophrenia [11], de-
pression [12], Alzheimer’s disease [13], Huntington’s chorea
[14], and alcohol withdrawal delirium [15].
Few studies have investigated BDNF levels in relation
to delirium with conflicting and inconclusive results. A
study in ICU patients [16] found that serum BDNF levels
were significantly higher in delirious patients compared
to nondelirious controls. In contrast, a study in oncology
inpatients [17] did not find any significant differences in
the serum levels of BDNF between delirious and nondeliri-
ous patients. Similarly, Tomasi et al. [18] in a study of
community-acquired pneumonia found that patients “with
sepsis-associated encephalopathy (SAE)” had higher levels
of BDNF compared to “delirious patients.” Another study
examining outcomes in ICU patients reported that low levels
of BDNF were associated with increased mortality [19]. The
pathophysiology of delirium has been understudied [20] and,
in particular, it remains uncertain how such a wide range
of potential aetiologies, many of which involve pathology at
peripheral body locations and without clear links to CNS
function, can produce such a consistent complex neuropsy-
chiatric picture that reflects generalized brain dysfunction.
Studies of prevalent delirium may miss associations that are
important during the early/developing phases of medical
illness and we therefore decided to explore the BDNF-
delirium relationship across the entire hospital stay of a group
of older medically ill people, in which there would be both
prevalent and incident delirium and to follow this to define
course as either recovering or continuous.Therefore, the aims
of the present study were (a) to investigate the relation of
BDNF to the occurrence of delirium (both incidence and
prevalence) and (b) the association of BDNF levels alongwith
other relevant factors in the recovery of delirium.
2. Materials and Methods
2.1. Design of the Study. The study is a prospective longitudi-
nal observational study.
2.2. Setting Inclusion/Exclusion Criteria. All acute medical
admissions of patients 70 years old and over to a University
Hospital in Sligo in the northwest of Ireland were approached
to enter the study within 72 hours of admission. Patients who
were admitted twice during the study period were included
only on their first admission. Patients who were in a terminal
phase of illness, with severe aphasia, intubated, with severe
sensory problems, or unable to speak English were excluded
from the study.
2.3. Clinical Assessments: Measurements Scales. Demograph-
ics (gender, age, years of education, marital status, and living
circumstances) were collected from the medical case notes
and from the hospital computerised database.
At each assessment, the following were carried out:
2.3.1. Cognitive Assessment. Montreal Cognitive Assessment
(MoCA) [21] was used to assess general cognition. Adminis-
tration typically takes about 12–15min. The MoCA is scored
on a 30-point scale. Higher scores indicate better cognitive
performance. If patients could not complete sections (e.g.,
due to visual impairment) it was standardized to give a
maximum score of 30.
2.3.2. Delirium Assessment. Delirium severity and pres-
ence/absence were measured using the Revised Delirium
Rating Scale (DRS-R-98) [22], a 16-item rating scale with
thirteen severity items and 3 diagnostic items. The 13-item
severity section can be scored separately from the 3-item
diagnostic section. The DRS-R98 severity scale score ranges
from0–39with higher scores indicatingmore severe delirium
[22]. A score of 16 ormore is compatible with the diagnosis of
delirium.We defined as having delirium those with a score of
16 and above in DRS-R98 severity score (categorical variable
yes/no) and consequently as recovered from delirium those
who did not have delirium for at least two assessments before
discharge [23].
2.3.3. Severity of Physical Illness. The Acute Physiology and
Chronic Health Evaluation II (APACHE II) [24] and its
subscale Acute Physiology Score (APS) were used to measure
severity of physical illness. This includes age, chronic illness,
and acute physiological disturbance. The latter is measured
with its subscale APS which has 11 items and each one can be
scored from 0 to 4 (4 is the worst).The range of APACHE II is
from 0 to 71 and an increased score is closely correlated with
more severe illness and subsequent risk of hospital death.
2.3.4. Diagnosis of Previous History of Dementia. Cases with
preexisting dementia were identified as a clear history of doc-
umented DSM-IV diagnosis dementia or by using the Short
Informant Questionnaire on Cognitive Decline (IQCODE)
with a cut-off point of ≥3.5. [25]
2.4. Procedures. All eligible and consenting patients had an
assessment at first recruitment day. Thereafter 7 more assess-
ments were carried out every 3 (±1) days if patients were in
hospital.Themaximumnumber of assessmentwas thus eight.
Venous samples of blood (nonfasting)were taken on the same
day of each assessment, centrifuged immediately (maximum
elapsed time 20 minutes), to avoid release of BDNF from
platelets, and stored at −70∘C until analysis. Levels of BDNF
were estimated with the ELISA method Promega BDNF
Emax(R) immunoassay system and are expressed in ng/mL.
2.5. Ethics. Informed consent was obtained using a previ-
ously published method [26]. Consent was obtained sepa-
rately for the withdrawn blood. The study was approved by
the Sligo University Hospital Research Ethics Committee.
2.6. Statistical Analysis. Data were analysed with SPSS v20.
Descriptive statistics are presented as means or counts and
percentages. To examine any significant effects of BDNF,
cognition, and the other measurements on delirium status,
the Generalized Estimating Equations (GEE) method was
used. This model takes into account all the data, allows for
missing values, and adjusts for correlations due to repeated
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assessments of each participant [27]. Because the dependent
variables were categorical the binominal distribution with
logit link was used. When the dependent variable was time-
variant (e.g., delirium/no delirium) the “unstructured” work-
ing correlation matrix was assumed and when the depen-
dent variable was time-invariant the “independent” working
correlation matrix was assumed. The best fitting model was
taken as the one with the lowest value of Corrected Quasi-
Likelihood under Independence Model Criterion (QICC).
3. Results
3.1. Descriptive Statistics of the Sample. The sample consisted
of 198 participants (mean age 80.63; SD: 6.81; range 70–
97). Of these 92 (46.5%) were females. Eighty-six (43.4%)
were identified with a history of dementia. Table 1 shows the
clinical characteristics of those with and without delirium at
each assessment, including ratings for the MoCA, APACHE
II, and BDNF levels at each assessment.
3.2.MissingValues. Evaluation ofmissing values using Little’s
MCAR test indicated that they were missing completely at
random (MCAR 𝜒2 = 12.24, df = 9, 𝑝 = 0.20).
3.3. Examination of the Effects of Potential Explanatory
Variables on the Presence or Absence of Delirium (Longitu-
dinal Analysis). Treating the subjects as random effects and
the number of assessments as repeated measurements, we
generated an initial GEE model (binomial, link function
logit) with the dependent variable as the presence or not of
delirium (as defined with the DRS-R98) at any assessment
and as independent variables the levels of BDNF, APACHE II,
MoCA scores, age, gender, and previous history of dementia.
After fitting differentmodels by systematically removing vari-
ables with nonsignificant effects and comparing the QICCs
a parsimonious model was achieved with the lowest QICC
value (Table 2).
Significant predictors for the presence of delirium were
previous history of dementia, older age, lower scores on
MoCA, and more severe physical illnesses as measured with
the APACHE II. Levels of BDNF did not have any significant
effect on the occurrence of delirium (Table 2).
3.4. Examination of the Effects of Explanatory Variables on
the Recovery of Delirium (Longitudinal Analysis). During the
observation period 140 participants (70.7 %) never developed
delirium. From the remaining 58, 19 (32.8%) recovered from
delirium (i.e., evidenced by the final two ormore assessments
being negative for delirium). After excluding those who never
developed delirium, we conducted a similar analysis with
the GEE model as above but with recovery or not from
delirium as the dependent variable and with the levels of
BDNF, APACHE II, and MoCA scores, age, gender, and
previous history of dementia as independent variables. The
final most parsimonious model is presented in Table 3 where
it can be seen that, after controlling for the other variables,
low levels of BDNF and higher MoCA scores were the only
independent predictors for delirium recovery. Figures 1 and
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Figure 1: BDNF levels: scatterplot of levels of BDNF across the time
between those who recovered from delirium and those who did not.
Fitted lines with Loess Kernel Epanechnikov method (90% points
fitted).
2 depict a graphic illustration of the levels of BDNF and
MoCA scores across the time between those who recovered
and thosewhodid not recover fromdeliriumusing fitted lines
as per the Loess Kernel Epanechnikov method (90% points
fitted). Regarding the BDNF (Figure 1), those who did not
recover had persistently lower levels of BDNF compared to
those who recovered. Regarding the MoCA scores (Figure 2)
thosewho recovered had steadily increasing scores during the
assessments.
4. Discussion
This longitudinal study confirms that delirium status is
associated with cognitive impairment as measured by the
MoCA, previous history of dementia, advanced age, and
severity of physical illness, in keeping with previous work
[28]. We did not find any significant association between
BDNF levels and delirium (incident or prevalent). In the
few previous studies that have been conducted there have
been variable findings; Brum et al. [17] did not find any
significant differences in the serum levels of BDNF between
delirious and nondelirious oncology patients, while Grandi
et al. [16] reported that serum BDNF levels were significantly
higher in delirious patients than in nondelirious controls in
an ICU setting. Given that BDNF is a neurotrophic factor
it might be expected that the occurrence of delirium would
if anything be linked to lower levels [29]. In keeping with
this assertion, lower levels of BDNF are associated with
delirium tremens [15]. However a direct comparison cannot
4 BioMed Research International
Table 1: Cases of delirium (according to DRS-R98 > 16) with ratings of theMoCA, APACHE II, and BDNF levels (ng/mL) at each assessment
point.
Assessments MOCA APACHE II BDNF (ng/mL)
(1)
No delirium
Mean 12.11 8.25 18.01
SD 7.66 3.30 7.35
Valid𝑁 157 162 67
Delirium
Mean 2.85 10.46 19.63
SD 2.61 4.79 3.62
Valid𝑁 34 35 11
(2)
No delirium
Mean 11.52 8.48 16.43
SD 8.22 3.58 7.79
Valid𝑁 117 123 41
Delirium
Mean 3.12 10.11 17.94
SD 2.47 4.13 4.75
Valid𝑁 26 27 13
(3)
No delirium
Mean 9.94 8.77 16.80
SD 7.88 3.70 7.41
Valid𝑁 72 74 25
Delirium
Mean 4.48 9.32 13.47
SD 3.08 3.22 3.64
Valid𝑁 21 25 10
(4)
No delirium
Mean 11.30 8.55 15.96
SD 7.48 3.44 7.67
Valid𝑁 50 51 17
Delirium
Mean 5.54 9.73 17.84
SD 3.13 3.37 5.48
Valid𝑁 13 15 5
(5)
No delirium
Mean 9.38 8.41 18.28
SD 7.16 3.05 6.74
Valid𝑁 39 41 10
Delirium
Mean 2.20 10.64 11.69
SD 1.93 3.56 3.01
Valid𝑁 10 11 3
(6)
No delirium
Mean 5.87 9.11 15.46
SD 4.94 3.38 6.55
Valid𝑁 23 27 7
Delirium
Mean 2.50 13.20 12.05
SD 2.38 4.76 1.81
Valid𝑁 4 5 2
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Table 1: Continued.
Assessments MOCA APACHE II BDNF (ng/mL)
(7)
No delirium
Mean 8.33 8.82 16.38
SD 6.99 3.80 5.88
Valid𝑁 21 22 10
Delirium
Mean 1.00 11.00 .
SD . . .
Valid𝑁 1 1 0
(8)
No delirium
Mean 11.78 7.78 15.15
SD 7.07 4.12 .78
Valid𝑁 9 9 3
Delirium
Mean 3.67 8.67 11.62
SD 1.15 2.89 10.21
Valid𝑁 3 3 2
Table 2: GEE model examining the effects of independent predictor variables on delirium status.
Parameter 𝐵 Std. error
95%Wald confidence
interval Hypothesis test
Lower Upper Wald chi-square df Sig.
Intercept 7.82 2.5763 2.773 12.872 9.219 1 .002
Prev hx of dementia = No .89 .3214 .266 1.526 7.770 1 .005
Prev hx of dementia = yes 0 . . . . . .
Age −.086 .0285 −.142 −.030 9.075 1 .003
MoCA .210 .0257 .160 .260 66.959 1 .000
APACHE II −.096 .0380 −.170 −.021 6.360 1 .012
apply as these two conditions have phenomenological and
aetiological differences; BDNF levels are increased in vitro
and in vivo following acute alcohol exposure but are reduced
with chronic use [30] and genetic variants are associated with
alcohol withdrawal delirium [31].
In addition, the results from the present study indicate
that lower initial levels of BDNF together with higher MoCA
scores are associated with a reduced frequency of delirium
recovery. Figure 2 depicts how an initial drop in BDNF levels
is followed by an increase in those who recover but not in
those who do not. No previous studies have investigated
the role of BDNF in recovery of delirium. It was reported
that the levels of BDNF were consistently low only in a
case report of a patient with systemic lupus erythematosus
who had continuous delirium [32]. Although normative data
do not exist (as different kits and different methods of
evaluation of the levels of BDNF produce different “normal
values”) previous research suggests that levels of BDNF
are slow to normalise [33]. Therefore we cannot conclude
from our findings that BDNF levels are normalised after
delirium recovery. However, a similar pattern exists for other
neuroprotective factors such as IGF-I [34] in which delirious
patients with lower initial levels of IGF-I were also those who
finally recovered from delirium. It appears that a feedback
mechanismmaintains levels of neuroprotective factors above
a minimum, and in those with delirium who eventually
recover the levels of neuroprotective factors steadily increase
over time [35].
We investigated levels of BDNF in peripheral blood. This
is likely to reflect levels of BDNF in the brain since studies
have shown that BDNF crosses the blood-brain barrier and
that BDNF levels in the brain and serum are closely correlated
[36, 37].
The present study, to our knowledge, is the first study
to investigate BDNF levels in delirium in older medical
inpatients and explore the association with recovery of delir-
ium. This lack of data makes comparison difficult and limits
efforts to formulate hypotheses around pathophysiological
mechanisms. Therefore, and in view of our relatively small
sample size, these results need to be interpreted with caution.
A limitation of this study is that patients were followed
only until their discharge from hospital, so the categorisation
of patients as recovered or not recovered from delirium
is compounded by other factors that resulted in patients’
overall clinical recovery or social circumstances allowing
their discharge from hospital. Finally, the study involved only
hospitalised patients, thus excluding patients with delirium in
the context of illness not resulting in hospital admission.
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Table 3: Parameter estimates and significant effects of independent variables on delirium recovery.
Parameter 𝐵 Std. error
95%Wald confidence interval Hypothesis test
Lower Upper Waldchi-square df Sig.
MoCA .069 .0311 .008 .130 4.933 1 .026
BDNF −.045 .0169 −.078 −.012 7.155 1 .007
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Figure 2: MoCA scores across the time for those who recovered
from delirium and those who did not. Fitted lines with Loess Kernel
Epanechnikov method (90% points fitted).
5. Conclusions
We did not find any association of BDNF levels with the
occurrence of delirium but identified an association with
recovery from delirium. If these findings are confirmed in
further studies then this would indicate that BDNF could be
used as a marker of recovery. Therefore, this suggests that
recovery from deliriummay be predicted based on biological
variables, which in turn has important clinical implications
for the prognosis and treatment of delirium.
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